Medexus Pharmaceuticals Inc. (CVE:MDP – Get Free Report)’s share price traded down 4.9% on Wednesday . The company traded as low as C$7.70 and last traded at C$7.75. 40,981 shares were traded during mid-day trading, a decline of 40% from the average session volume of 68,619 shares. The stock had previously closed at C$8.15.
Medexus Pharmaceuticals Price Performance
The stock has a fifty day simple moving average of C$7.75 and a 200-day simple moving average of C$7.75. The company has a current ratio of 1.19, a quick ratio of 0.74 and a debt-to-equity ratio of 1,174.36. The company has a market capitalization of C$148.54 million and a PE ratio of -4.28.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.
Featured Articles
- Five stocks we like better than Medexus Pharmaceuticals
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Pros And Cons Of Monthly Dividend Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Financial Services Stocks Investing
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
